On August 1, 2018 Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, reported that it will report financial results for the three and six-month periods ended June 30, 2018, on Wednesday, August 8 after the markets close (Press release, Foamix, AUG 1, 2018, View Source [SID1234528363]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Due to the proximity of the Company receiving data from the confirmatory Phase 3 study of FMX101 in acne, the Company will not be hosting an earnings conference call. As previously disclosed, the Company expects to announce top line results from this Phase 3 study in acne during this current quarter and will address investor questions, including those regarding financial results, at that time